ACST
Income statement / Annual
Last year (2025), Acasti Pharma Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Acasti Pharma Inc.'s net income was -$12.77 M.
See Acasti Pharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
02/29/2016 |
02/28/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$196.00 K |
$0.00 |
$0.00 |
$0.00 |
$27.79 K |
$216.29 K |
| Cost of Revenue |
$0.00
|
$11.00 K
|
$52.16 M
|
$15.59 M
|
$76.00 K
|
$2.32 M
|
$2.33 M
|
$0.00
|
$60.08 K
|
$187.90 K
|
| Gross Profit |
$0.00
|
-$11.00 K
|
-$52.16 M
|
-$15.59 M
|
$120.00 K
|
-$2.32 M
|
-$2.33 M
|
$0.00
|
-$32.29 K
|
$28.39 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0.61
|
0
|
0
|
0
|
-1.16
|
0.13
|
| Research and Development Expenses |
$9.51 M
|
$4.63 M
|
$9.97 M
|
$5.56 M
|
$4.17 M
|
$15.97 M
|
$28.73 M
|
$12.13 M
|
$5.45 M
|
$5.21 M
|
| General & Administrative Expenses |
$7.17 M
|
$6.43 M
|
$8.08 M
|
$9.26 M
|
$5.51 M
|
$8.16 M
|
$4.24 M
|
$3.12 M
|
$1.61 M
|
$4.72 M
|
| Selling & Marketing Expenses |
$0.00
|
$341.34 K
|
$136.00 K
|
-$518.00 K
|
$1.14 M
|
-$2.67 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.17 M
|
$6.18 M
|
$6.95 M
|
$9.78 M
|
$6.66 M
|
$8.46 M
|
$4.24 M
|
$3.12 M
|
$1.61 M
|
$4.72 M
|
| Other Expenses |
$0.00
|
$0.00
|
$63.00 K
|
$0.00
|
$5.71 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$16.68 M
|
$11.30 M
|
$18.25 M
|
$15.34 M
|
$10.84 M
|
$19.11 M
|
$32.97 M
|
$15.25 M
|
$7.06 M
|
$9.94 M
|
| Cost And Expenses |
$0.00
|
$11.31 M
|
$18.25 M
|
$13.18 M
|
$16.62 M
|
$24.44 M
|
$32.97 M
|
$15.25 M
|
$7.12 M
|
$10.12 M
|
| Interest Income |
$0.00
|
$0.00
|
$246.00 K
|
$77.00 K
|
$107.00 K
|
$336.00 K
|
$355.75 K
|
$55.75 K
|
$54.24 K
|
$69.54 K
|
| Interest Expense |
$0.00
|
$911.00 K
|
$67.69 M
|
$224.00 K
|
$264.00 K
|
$247.00 K
|
$273.37 K
|
$283.41 K
|
$1.67 K
|
$3.24 K
|
| Depreciation & Amortization |
$0.00
|
$11.00 K
|
$124.00 K
|
$1.16 M
|
$924.00 K
|
$2.32 M
|
$2.73 M
|
$2.67 M
|
$1.77 M
|
$1.87 M
|
| EBITDA |
$0.00 |
-$14.62 M |
-$2.42 M |
-$19.99 M |
-$9.79 M |
-$33.33 M |
-$30.99 M |
-$14.01 M |
-$5.27 M |
-$7.97 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-49.96
|
0
|
0
|
0
|
-189.69
|
-36.85
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-83.77
|
0
|
0
|
0
|
-255.25
|
-45.8
|
| Total Other Income/Expenses Net |
$0.00
|
-$3.32 M
|
-$45.63 M
|
$4.71 M
|
-$3.26 M
|
-$1.51 M
|
-$4.91 M
|
-$1.40 M
|
$2.43 M
|
$8.52 M
|
| Income Before Tax |
-$12.77 M
|
-$14.69 M
|
-$51.97 M
|
-$10.47 M
|
-$19.68 M
|
-$25.51 M
|
-$38.62 M
|
-$16.65 M
|
-$6.32 M
|
-$1.32 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-100.4
|
0
|
0
|
0
|
-227.33
|
-6.12
|
| Income Tax Expense |
$0.00
|
-$1.78 M
|
-$9.54 M
|
-$648.00 K
|
$0.00
|
$247.00 K
|
$5.24 M
|
$291.15 K
|
-$2.38 M
|
-$8.52 M
|
| Net Income |
-$12.77 M
|
-$12.85 M
|
-$42.43 M
|
-$9.82 M
|
-$19.68 M
|
-$25.76 M
|
-$43.86 M
|
-$16.94 M
|
-$4.66 M
|
-$1.32 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-100.4
|
0
|
0
|
0
|
-167.73
|
-6.12
|
| EPS |
-0.79 |
-1.35 |
-5.71 |
-1.6 |
-7.96 |
-8.38 |
-6.46 |
-7.75 |
-20.99 |
-5.98 |
| EPS Diluted |
-0.79 |
-1.35 |
-5.71 |
-1.6 |
-7.96 |
-8.48 |
-6.46 |
-7.75 |
-20.99 |
-5.98 |
| Weighted Average Shares Out |
$12.09 M
|
$9.53 M
|
$7.44 M
|
$6.14 M
|
$2.47 M
|
$3.07 M
|
$6.79 M
|
$2.19 M
|
$222.08 K
|
$221.20 K
|
| Weighted Average Shares Out Diluted |
$12.09 M
|
$9.53 M
|
$7.44 M
|
$6.14 M
|
$2.47 M
|
$3.04 M
|
$6.79 M
|
$2.19 M
|
$222.08 K
|
$221.20 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
